Dynomics
Heart failure affects 4% of the US population, yet treatment options are primarily symptomatic, including blood thinners, assistive devices and heart transplant. Patients today face a 50% 5-year survival rate upon diagnosis. It’s time to change that. Our approach is to engineer human cardiac organoids that function similarly to adult human heart tissue, enabling us to directly target therapeutics to the heart. We aim to address the root cause of heart failure and restore heart function.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
7
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
16
organic / mo
Sign up free to see all 3 verified contacts at Dynomics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
- BG
Brendan Griffen
() · Other
EmailPhone - DT
Drew Titmarsh
-, · Other
EmailPhone - TD
Tom Deckwerth
Vice President, Therapeutic Development · Healthcare & Human Services
EmailPhone
Showing 3 of 3 verified contacts
Top roles at Dynomics
3 distinct titles indexed · top 3 shown.
- 1()
- 1-,
- 1vice president, therapeutic development
Sign up to unlock all 3 contacts at Dynomics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Dynomics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.